CN1824080A - Medicinal composition for antivirus and its preparation method - Google Patents
Medicinal composition for antivirus and its preparation method Download PDFInfo
- Publication number
- CN1824080A CN1824080A CN 200510121132 CN200510121132A CN1824080A CN 1824080 A CN1824080 A CN 1824080A CN 200510121132 CN200510121132 CN 200510121132 CN 200510121132 A CN200510121132 A CN 200510121132A CN 1824080 A CN1824080 A CN 1824080A
- Authority
- CN
- China
- Prior art keywords
- herba violae
- radix scutellariae
- extract
- antiviral
- part group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
An antivirus composite Chinese medicine is prepared from scutellaria root, Tokyo violet herb and the pharmacologically acceptable additives through extracting their active components. Its preparing process and quality control method are also disclosed.
Description
Technical field:
The present invention relates to a kind of antiviral medicinal composition, particularly a kind of hepatitis B virus and HIV virus of being applied to derives from pharmaceutical composition of Radix Scutellariae and Herba Violae and preparation method thereof.
Background technology:
Radix Scutellariae is the root of labiate Radix Scutellariae, has heat clearing away, pathogenic fire purging, detoxifcation, hemostasis, effect such as antiabortive, and pharmacological action is extensive.In recent years, Chinese scholars has been carried out a large amount of research to it, and has reached higher level, and the main effective ingredient of modern study proof Radix Scutellariae is a baicalin.Baicalin is a flavone compound, and it alleviates the tissue ischemia reperfusion injury removing interior free yl, regulates immunologic function, and aspects such as hepatic cholagogic, infection, antitumor all have certain effect, and are the constituent of plurality of Chinese preparation.
The baicalin chemical structural formula
Modern study shows that baicalin can suppress duplicating of hepatitis B virus and HIV virus.
Herba Violae is the dry herb of Violaceae Chinese violet Viola yedoensis Makino.Spring, Qiu Erji gather, and remove impurity, dry.Bitter in the mouth, suffering, cold in nature.GUIXIN, Liver Channel.Heat-clearing and toxic substances removing, the removing heat from blood detumescence.Herb contains the esters of polysaccharide, saponin, flavonoid, wax, cerinic acid and unsaturated acids.Modern study shows that the polysaccharide component with Herba Violae has the effect that suppresses HIV (human immunodeficiency virus) on cell culture medium, and its polysaccharide component can strengthen body immunity simultaneously.
As everyone knows, hepatitis B and acquired immune deficiency syndrome (AIDS) equally all are the diseases that threatens human health or even life, and being used for antiviral drug at present is not that DeGrain is exactly that medical expense is too high, is not suitable for China's national situation.This just requires us to develop determined curative effect, antiviral drugs with low cost, the Chinese medicine culture is of extensive knowledge and profound scholarship, the herbal species of heat-clearing and toxic substances removing is numerous, and therefrom the specific medicament of exploitation treatment difficult miscellaneous diseases, severe crisis is an important directions of China's modernization of Chinese medicine.Radix Scutellariae and Herba Violae tradition just are used for heat-clearing and toxic substances removing, we are by a large amount of influencing each other property experiments, it is unexpected that the two flavor medical materials of finding have good synergism through the effective site of extracting the purification gained on antiviral effect, can reach the purpose of efficacy enhancing and toxicity reducing, this is not that those of ordinary skill just can be found without performing creative labour.Find the effective ingredient in Radix Scutellariae and the Herba Violae neither the ordinary person thinkable, and the two mix the phenomenon of using and whether can obtain the appropriate formulation form neither be conspicuous.
Summary of the invention:
One of purpose of the present invention provides a kind of antiviral medicinal composition, and another object of the present invention provides a kind of preparation method of anti-viral pharmaceutical compositions.
In order to achieve the above object, the present invention has taked following technological means:
We provide a kind of antiviral medicinal composition, and it is antiviral " effective part group " and the pharmaceutically acceptable pharmaceutic adjuvant composition that origin comes from Radix Scutellariae and two kinds of Chinese crude drugs of Herba Violae, and wherein " effective site " group is:
1) from the total extract that extracts 10: 1 to 1: 3 ratio (between preferred 4: 1 to 1: 2) blended Radix Scutellariaes and the Herba Violae two flavor medical materials; Or
2) Radix Scutellariae and Herba Violae ratio from 10: 1 to 1: 3 the two flavor Radix Scutellariae extracts that extract respectively of medical materials of (between preferred 4: 1 to 1: 2) and the Herba Violae extract mixture of compound composition again; Or
3) mixture of being made up of in 10: 1 to 1: 3 ratio baicalin and Herba Violae extract, the ratio of preferred baicalin and Herba Violae is 2: 1.
The contained content of baicalin of our described effective part groups is not less than 25% of mixture weight.Can reach more than 80% of mixture weight through the content that is further purified baicalin and viola yedoensis, and the easier control of quality, better efficacy.
The above Herba Violae extract can be the viola yedoensis part of extracting.This viola yedoensis is rich in sulfide polysaccharide.
More than be used to extract between also preferred 3: 1 to 1: 1 of the amount ratio of the Radix Scutellariae of effective part group and Herba Violae.Most preferably be used to extract the Radix Scutellariae of effective part group and the amount of Herba Violae is 2: 1.
We also provide a kind of preparation to derive from the method for antiviral " effective part group " of Radix Scutellariae and two kinds of medical materials of Herba Violae, may further comprise the steps:
1) gets Radix Scutellariae and Herba Violae medical material in 10: 1 to 1: 3 ratio;
2) radix scutellariae medicinal materials adds 8-12 times of water gaging decoction twice, each 1-2 hour, filters, filtrate adds hydrochloric acid and regulates pH value to 1-2, and 80 ℃ of insulation 30-60min leave standstill centrifugation, precipitation adds suitable quantity of water and stirs evenly and add 40% sodium hydroxide and regulate pH value to neutral, adds equivalent ethanol, filters, subsequent filtrate adds hydrochloric acid and regulates pH value to 1-2, fully stirs, and is heated to 80 ℃ of insulation 30-60min and leaves standstill, centrifugation, precipitation washing, 50% washing with alcohol, reuse 95% ethyl alcohol recrystallization gets Radix Scutellariae extract;
3) Herba Violae decocts with water twice, merge extracted twice liquid and be concentrated into relative density 1.15-1.25 (50 ℃), fully stir the ethanol standing over night that adds equivalent down, remove precipitation, reclaiming ethanol (can be D101 to there not being alcohol flavor back with macroporous adsorbent resin, ADS-7, SA-1, HPD-300, the AB-8 macroporous adsorbent resin) removes the ester soluble components, effluent and water elution liquid merge, with the ultrafilter membrane ultrafiltration of the molecular weight 5000 that dams, ultrafiltrate be concentrated into most dry Herba Violae extract;
4) Radix Scutellariae extract and Herba Violae extract uniform mixing are got described " effective part group ", contain baicalin and viola yedoensis.
Above quality of medicinal material ratio is preferably between 3: 1 to 1: 1.More preferably the quality of medicinal material of Radix Scutellariae and Herba Violae is 2: 1.The preferred ADS-7 resin of macroporous adsorbent resin.
We also provide the application of this pharmaceutical composition in preparation anti-hepatitis virus and HIV (human immunodeficiency virus) medicine.
The present invention creatively unites use with Radix Scutellariae and Herba Violae, selects two flavor medical material antivirus effective positions and makes pharmaceutical composition and preparation by a large amount of testing sieves.We find by suppressing the virus test in external and the body, pharmaceutical composition of the present invention suppresses effect (and different proportioning effects also has bigger difference) because synergistic existence has produced beyond thought good virus, especially hepatitis B virus and HIV virus has been duplicated the good restraining function.This preparation of pharmaceutical compositions method process stabilizing that we provide, favorable reproducibility.We have also established quality standard by modern analysis means and fingerprint pattern technology, find that the pharmaceutical composition that we provide is quality controllable, and good stability can further be developed as novel antiviral drugs.
Specific embodiment:
Embodiment 1: the preparation of Radix Scutellariae and Herba Violae compound injection
Get radix scutellariae medicinal materials 1000g, add the 10L deionized water and decoct twice, each 1.5 hours, filter, filtrate adds hydrochloric acid and regulates pH value to 1-2, and 80 ℃ of insulation 45min leave standstill, centrifugation, precipitation add suitable quantity of water and stir evenly and add 40% sodium hydroxide and regulate pH value to neutral, add equivalent ethanol, filter, subsequent filtrate adds hydrochloric acid and regulates pH value to 1-2, fully stirs, be heated to 80 ℃ of insulation 45min and leave standstill, centrifugation, precipitation washing, 50% washing with alcohol, reuse 95% ethyl alcohol recrystallization gets Radix Scutellariae extract;
Getting the 500g Herba Violae decocts with water twice, each 5000ml decocted two hours, merge extracted twice liquid and be concentrated into relative density 1.20-1.25 (50 ℃), fully stir the ethanol standing over night that adds equivalent down, remove precipitation, reclaim ethanol and do not remove the ester soluble components to there being alcohol flavor back with macroporous adsorbent resin (ADS-7 macroporous adsorbent resin), effluent and 1 times of bed volume water elution liquid merge, with the ultrafilter membrane ultrafiltration of the molecular weight 5000 that dams, ultrafiltrate be concentrated into most dry Herba Violae extract;
With Radix Scutellariae extract and Herba Violae extract uniform mixing, adding 500ml water for injection fully dissolves, the cold preservation after-filtration that spends the night, subsequent filtrate adds the sodium chloride of 9g, fully add water for injection to 1000ml after the dissolving, regulate pH value to 6-7, add active carbon and be sub-packed in the 100ml infusion bottle, sterilization except that behind the thermal source.Sample number into spectrum: HQZS-1
Embodiment 2: the preparation of injection Radix Scutellariae and Herba Violae lyophilized powder
Get radix scutellariae medicinal materials 1000g, add the 10L deionized water and decoct twice, each 1.5 hours, filter, filtrate adds hydrochloric acid and regulates pH value to 1-2, and 80 ℃ of insulation 45min leave standstill, centrifugation, precipitation add suitable quantity of water and stir evenly and add 40% sodium hydroxide and regulate pH value to neutral, add equivalent ethanol, filter, subsequent filtrate adds hydrochloric acid and regulates pH value to 1-2, fully stirs, be heated to 80 ℃ of insulation 45min and leave standstill, centrifugation, precipitation washing, 50% washing with alcohol, reuse 95% ethyl alcohol recrystallization gets Radix Scutellariae extract;
Getting the 500g Herba Violae decocts with water twice, each 5000ml decocted two hours, merge extracted twice liquid and be concentrated into relative density 1.20-1.25 (50 ℃), fully stir the ethanol standing over night that adds equivalent down, remove precipitation, reclaim ethanol and do not remove the ester soluble components to there being alcohol flavor back with macroporous adsorbent resin (ADS-7 macroporous adsorbent resin), effluent and 1 times of bed volume water elution liquid merge, with the ultrafilter membrane ultrafiltration of the molecular weight 5000 that dams, ultrafiltrate be concentrated into most dry Herba Violae extract;
With Radix Scutellariae extract and Herba Violae extract uniform mixing, adding 250ml water for injection fully dissolves, the cold preservation after-filtration that spends the night, subsequent filtrate add 32g's, fully add water for injection to 400ml after the dissolving, regulate pH value to 6-7, add and cross 0.22 micron microporous filter membrane after active carbon removes thermal source, be sub-packed in the 7ml cillin bottle, jump a queue, lyophilizing, gland are promptly.Sample number into spectrum: HQDD-1
Embodiment 3: the preparation of injection Radix Scutellariae and Herba Violae lyophilized powder
Press the method for embodiment 2, writing out a prescription is
Radix Scutellariae: 10kg
Herba Violae: 1kg
Make 1000.Sample number into spectrum: HQDD-2
Embodiment 4: the preparation of injection Radix Scutellariae and Herba Violae lyophilized powder
Press the method for embodiment 2, writing out a prescription is
Radix Scutellariae: 12kg
Herba Violae: 2kg
Make 1000.Sample number into spectrum: HQDD-3
Embodiment 5: the preparation of injection Radix Scutellariae and Herba Violae lyophilized powder
Press the method for embodiment 2, writing out a prescription is
Radix Scutellariae: 9kg
Herba Violae: 3kg
Make 1000.Sample number into spectrum: HQDD-4
Embodiment 6: the preparation of injection Radix Scutellariae and Herba Violae lyophilized powder
Press the method for embodiment 2, writing out a prescription is
Radix Scutellariae: 3kg
Herba Violae: 6kg
Make 1000.Sample number into spectrum: HQDD-5
Embodiment 7: the preparation of injection Radix Scutellariae and Herba Violae lyophilized powder
Herba Violae is pressed the method for embodiment 2, and baicalin directly feeds intake.Prescription is
Baicalin: 40g
Herba Violae extract: 20g
Make 1000.Sample number into spectrum: HQDD-6
Embodiment 8: the preparation of injection Radix Scutellariae and Herba Violae lyophilized powder
Baicalin: 30g
Herba Violae extract: 30g
Make 1000.Sample number into spectrum: HQDD-7
Embodiment 9: the preparation of Radix Scutellariae and Herba Violae compound capsules
Make Radix Scutellariae extract (or by the baicalin that directly feeds intake of writing out a prescription) and Herba Violae extract respectively, behind the uniform mixing, add soybean oil, Cera Flava, mixing is made soft capsule, promptly.
Embodiment 10: the preparation of Radix Scutellariae and Herba Violae compound capsule
Make Radix Scutellariae extract (or by the baicalin that directly feeds intake of writing out a prescription) and Herba Violae extract respectively, behind the uniform mixing, add 10% dextrin, granulate, make capsule, promptly.
Embodiment 11: the preparation of Radix Scutellariae and Herba Violae compound tablet
Make Radix Scutellariae extract (or by the baicalin that directly feeds intake of writing out a prescription) and Herba Violae extract respectively, add microcrystalline Cellulose behind the uniform mixing, crospolyvinylpyrrolidone, pulverize, ethanol is softening, granulates 50 ℃ of dryings behind 60 mesh sieves excessively, cross 60 mesh sieve granulate, add carboxymethyl starch sodium, Aspartane, magnesium stearate uniform mixing, compacting, promptly.
The external anti-HBV influence of embodiment 12:HQDD medicine
Experiment medicine: HQDD-2, HQDD-1, HQDD-6 powder pin (embodiment is seen in section's preparation in the Guangdong, presses the crude drug amount and regulates consumption)
The DMEM culture fluid, hyclone, penicillin, streptomycin, glutaminase, trypsin, MTT, DMSO.
Normal saline
Experiment cell: 2.2.15 cell strain.
Experimental technique: the 2.2.15 cell strain is to change clone's HBV-DNA and anti-6418 plasmids over to human hepatoma cell strain HepG2 simultaneously and set up with the cotransfection method, can secrete HbsAg, HBcAg and complete Dane granule steadily in the long term, be external anti-HBV drug screening at present and estimate cell model preferably.2.2.15 cell DMEM culture fluid, culture fluid adds 10% hyclone, the 100U/ml penicillin, and the 100U/ml streptomycin, 80ug/ml G418,0.03% glutaminase is transferred pH to 6.8 with 0.238%Hepes.With 0.06% trypsin the 2.2.15 cell is dispersed into the individual cells suspension, by 3 * 10
4Cell/0.1ml/ hole branch is planted in 96 orifice plates, uses the pastille culture fluid behind the 2d instead, and each concentration adds four holes, and according to the preliminary experiment result, 3 groups of HQDD powder pins are diluted to 8 dense 10g/ml respectively with cell maintenance medium, 5mg/ml, and 2.50mg/ml,
1.25g/ml, 0.625mg/ml, 0.312mg/ml, 0.156mg/ml, 0.078mg/ml, and establish blank group and cell matched group.Behind cytosis 11d, suct clear liquid and measure HBsAg and HBeAg with the ELISA method, remaining cell is measured drug cell toxicity with mtt assay.Mtt assay is measured the half toxic concentration of medicine cell growth, add 400ug/ml MTT 0.1ml/ hole to cell, 37 ℃ of 5%CO2 are hatched 4h, as seen the yellow black first is collected together granule, discards MTT liquid, adds 100%DMSO 0.1ml/ hole, after treating that first is collected together granule and dissolved (about 10min) fully, measure the OD value with microplate reader 570nm wavelength, blank is established four holes, adds 100%DMSO 0.1ml/ hole.Be calculated as follows half toxic concentration (TC
50).
A=log＞50% drug level
B=log＜50% drug level
C＝A-B
The detection of HBsAg, HBeAg is adopted ELISA to measure box and is detected.Measure every hole OD value with microplate reader 450/630nm dual wavelength, and calculate the medium effective concentration (IC of medicine
50)
A=log＞50% drug level
B=log＜50% drug level
C＝A-B
Therapeutic index (TI) TI=TC
50/ IC
50
The results are shown in Table 1.
3 groups of HQDD powder of table 1 are at 2.2.15 cell strain evaluation of effect
| Medicine | HBsAg | HbeAg | TC50 (mg/ml) | ||
| IC50(mg/ml) | TI | IC50(mg/ml) | TI | ||
| HQDD-2 HQDD-1 HQDD-6 | 0.42 0.25 0.34 | 22.11 81.36 57.46 | 0.55 0.38 0.46 | 16.89 53.52 42.45 | 9.29 20.34 19.53 |
The outer anti HIV experiment research of embodiment 13:HQDD powder needle body
Experiment medicine: HQDD-2, HQDD-1, HQDD-6 powder pin, (embodiment is seen in section's preparation in the Guangdong, presses the crude drug amount and regulates consumption)
AZT (azidothymidine AZT)
Thin breast and virus: HIV-1IIB virus, MT4 cell.
Experimental technique: the HQDD powder at the toxicity test of MT4 cell with MT4 cell 2 * 10
5Individual/ml is inoculated in 96 orifice plates, every hole 0.1ml, add 3 groups of HQDD powder pins (being diluted to 1000-7.8ug/ml for continuous 2 times) with DMSO, 2 times of dilutions of positive control drug AZT (azidothymidine AZT) are 1000-7.8ug/ml, each concentration is inoculated 3 holes, establishes the normal cell contrast simultaneously, DMSO solvent control and empty from MT4 cell contrast (not adding virus), put 37 ℃, 5%CO
2Cultivate 6d in the incubator.Mtt assay is measured cytoactive, note CC
50Value.
3 groups of HQDD powder are induced the cytopathic inhibitory action of MT4 at HIV
Virus virulence is measured with 8 concentration HIV of 10 times of dilutions, observes the MT4 cytopathy in culture fluid RPMI-1640, calculates TCID
50Be 10
-6, with MT4 cell 2 * 10
5Individual/ml is inoculated in 96 orifice plates, and every hole is 0.1ml, adds 1000TCID respectively
50HIV virus 100ul, establish normal cell contrast and virus control simultaneously, add the 3 groups of HQDD powder pins and the AZT 100ul of 5 concentration of 2 times of dilutions then respectively, each sample concentration is all established 3 parallel holes, puts 37 ℃, 5%CO
2Cultivate in the incubator, behind the 72h under inverted microscope observation of cell pathological changes (CPE).CPF criterion: no syncytium formation ", no syncytium forms but cell irregular " ± ", has or not syncytium to form "+".
EC
50Judgement:
(1) only 1 hole is "+", and two holes are "-" or "-" and " ± " in addition, and this drug level can be considered EC
50
(2) 3 holes are respectively "+", ", with " ± ", this drug level can be considered EC
50
(3) 3 holes are " ± " this drug level and can be considered EC
50
(4) 3 holes are "+", and 3 holes under the next mass action are "-", and the intermediate value of two concentration can be considered EC
50
Selection index (SI): CC
50/ EC
50The results are shown in Table 2.
3 groups of HQDD powder of table 2 are at cultivating system to HIV-1 inducing cell pathological changes evaluation of effect at HIV-1/MT4
| Medicine | EC 50(ug/ml) | CC 50(ug/ml) | SI |
| AZT HQDD-2 HQDD-1 HQDD-6 | 0.1 5 2.5 3.75 | 500 1000 1000 1000 | 5000 200 500 266 |
Claims (16)
1, a kind of antiviral medicinal composition is characterized in that it is antiviral " effective part group " and the pharmaceutically acceptable pharmaceutic adjuvant composition that origin comes from Radix Scutellariae and two kinds of Chinese crude drugs of Herba Violae, and wherein " effective site " group is:
(1) from by the total extract that extracts the Radix Scutellariae of 10: 1 to 1: 3 mixed and the Herba Violae two flavor medical materials; Or
(2) Radix Scutellariae and Herba Violae ratio are from 10: 1 to 1: 3 the two flavor Radix Scutellariae extracts that extract respectively of medical materials and the Herba Violae extract mixture of compound composition again; Or
(3) mixture of forming in 10: 1 to 1: 3 ratio by baicalin and Herba Violae extract.The contained content of baicalin of described effective part group is not less than 25% of mixture weight.
2,, it is characterized in that the contained content of baicalin of described effective part group is not less than 80% of mixture weight as claim 1 described anti-viral pharmaceutical compositions.
3,, it is characterized in that the viola yedoensis of described Herba Violae extract for extracting as claim 1 or 2 described anti-viral pharmaceutical compositions.
4, as claim 1 described antiviral medicinal composition, the amount ratio that it is characterized in that being used to extracting the Radix Scutellariae of effective part group (1) or (2) and Herba Violae is between 4: 1 to 1: 2.
5, as claim 4 described antiviral medicinal compositions, the amount ratio that it is characterized in that being used to extracting the Radix Scutellariae of effective part group and Herba Violae is between 3: 1 to 1: 1.
6,, it is characterized in that being used to extract the Radix Scutellariae of effective part group and the amount of Herba Violae is 2: 1 as claim 5 described antiviral medicinal compositions.
7, as claim 1 described anti-viral pharmaceutical compositions, it is characterized by is to mix at 2: 1 with the mass ratio of Herba Violae extract by baicalin.
8,, it is characterized in that Herba Violae extract is meant the viola yedoensis that is rich in sulfide polysaccharide as claim 7 described anti-viral pharmaceutical compositions.
9, as each the pharmaceutical composition among the claim 1-8, can exist with any one dosage form pharmaceutically, comprise injection lyophilized powder, liquid drugs injection, transfusion, tablet, capsule, soft capsule, oral liquid.
10,, it is characterized in that dosage form is injection or injection lyophilized powder as claim 9 described pharmaceutical compositions.
11, a kind of preparation derives from the method for antiviral " effective part group " of Radix Scutellariae and two kinds of medical materials of Herba Violae, it is characterized in that may further comprise the steps:
1) gets Radix Scutellariae and Herba Violae medical material in 10: 1 to 1: 3 ratio;
2) radix scutellariae medicinal materials adds 8-12 times of water gaging decoction twice, each 1-2 hour, filters, filtrate adds hydrochloric acid and regulates pH value to 1-2, and 80 ℃ of insulation 30-60min leave standstill centrifugation, precipitation adds suitable quantity of water and stirs evenly and add 40% sodium hydroxide and regulate pH value to neutral, adds equivalent ethanol, filters, subsequent filtrate adds hydrochloric acid and regulates pH value to 1-2, fully stirs, and is heated to 80 ℃ of insulation 30-60min and leaves standstill, centrifugation, precipitation washing, 50% washing with alcohol, reuse 95% ethyl alcohol recrystallization gets Radix Scutellariae extract;
3) Herba Violae decocts with water twice, merge extracted twice liquid and be concentrated into relative density 1.15-1.25 (50 ℃), fully stir the ethanol standing over night that adds equivalent down, remove precipitation, reclaim ethanol and do not remove the ester soluble components with macroporous adsorbent resin to there being alcohol flavor back, effluent and water elution liquid merge, with the ultrafilter membrane ultrafiltration of the molecular weight 5000 that dams, ultrafiltrate be concentrated into most dry Herba Violae extract;
4) Radix Scutellariae extract and Herba Violae extract uniform mixing are got described " effective part group ", contain baicalin and viola yedoensis.
12,, it is characterized in that the quality of medicinal material ratio of Radix Scutellariae and Herba Violae is between 3: 1 to 1: 1 as claim 11 described methods.
13, as claim 12 described methods, the quality of medicinal material that it is characterized in that Radix Scutellariae and Herba Violae is 2: 1.
14,, it is characterized in that when Herba Violae is removed the ester soluble components can be D101, ADS-7, SA-1, HPD-300, AB-8 macroporous adsorbent resin as claim 11 described methods.
15, as claim 14 described methods, what it is characterized in that using is the ADS-7 resin.
16, as the application of claim 1 described pharmaceutical composition in the preparation antiviral drugs, comprise the application in anti-hepatitis virus or the anti AIDS virus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510121132 CN1824080A (en) | 2005-12-27 | 2005-12-27 | Medicinal composition for antivirus and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510121132 CN1824080A (en) | 2005-12-27 | 2005-12-27 | Medicinal composition for antivirus and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1824080A true CN1824080A (en) | 2006-08-30 |
Family
ID=36935021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510121132 Pending CN1824080A (en) | 2005-12-27 | 2005-12-27 | Medicinal composition for antivirus and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1824080A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106038725A (en) * | 2016-07-16 | 2016-10-26 | 周长征 | Method for separating anti-RSV-virus effective constituents after compatibility of pulsatilla chinensis and holotrichia diomphalia extracts |
-
2005
- 2005-12-27 CN CN 200510121132 patent/CN1824080A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106038725A (en) * | 2016-07-16 | 2016-10-26 | 周长征 | Method for separating anti-RSV-virus effective constituents after compatibility of pulsatilla chinensis and holotrichia diomphalia extracts |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101040924A (en) | Chinese traditional medicine for treating fowl coccidiosis and the preparing method thereof | |
| CN1813900A (en) | Kadsura longipedunculata lignin extract and its preparing method and use | |
| CN1775261A (en) | Mingmu-Dihuang preparation and new preparing method | |
| CN1533801A (en) | Golden hairpin dendrobium extract and its medicinal composition | |
| CN1965853A (en) | Application of gentiopicroside in preparation of antiviral medicament | |
| CN1686377A (en) | Chuankezhi (pant treating) powder injection and its preparation method | |
| CN1931190A (en) | Toad skin extract and its medicine prepn and their prepn | |
| CN1724014A (en) | Extractive of total saponin of clematis root, prepn. method and pharmaceutical use thereof | |
| CN1618441A (en) | Medicinal composition for regulating blood fat, prepn. method and use thereof | |
| CN1824080A (en) | Medicinal composition for antivirus and its preparation method | |
| CN1931230A (en) | Isodon lophanthoides extract and its prepn process and application | |
| CN100341537C (en) | Composition for treatment of B-type hepatitis and liver cirrhosis | |
| CN1887316A (en) | Chinese medicine composition and its prepn process and application | |
| CN1883619A (en) | Pharmaceutical composition of viola yedoensis and method for preparing same | |
| CN1682819A (en) | Sihuang intense heat purging dripping pill and its preparing method | |
| CN1795901A (en) | Medication for removing toxic heat, eliminating wetness and treating jaundice | |
| CN1291727C (en) | Chinese medicinal composition for treating cardiovascular disease, preparation and use thereof | |
| CN1785212A (en) | Novel cinobufogenin freeze-drying powder injection, its prepn. method and quality control method | |
| CN1310635C (en) | Medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1297568C (en) | Echinacea polysaccharide, and its preparing method and use for preparing medicines for treating antivirus and antibacterial, especially anti SARS | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN103211864B (en) | Melastoma dodecandrum Lour extract product and application of Melastoma dodecandrum Lour in preparation of medicines for treating AIDS | |
| CN1278698C (en) | Freeze dried injection of seeding of autumnal sowthistle-leaf ixeris and preparation method thereof | |
| CN1939390A (en) | Medicinal composition and its making method | |
| CN1651002A (en) | Chinese medicinal composition, its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |